Last updated: July 5, 2026
What is PROMETH VC PLAIN and how is it used in the market?
PROMETH VC PLAIN is a branded, combination cough/cold product marketed in “plain” format. In most markets where promethazine-containing cough/cold products are sold, the product competes in the OTC cough-cold and symptomatic relief segment, typically against multi-ingredient cough syrups, antihistamine-containing liquids, and alternative branded formulations.
How the product typically positions commercially
- Symptomatic relief category: cough, runny nose, and related cold/flu discomfort (formulation-dependent)
- Purchase driver: OTC availability, price-per-dose, label claims, and local brand preference
- Channel driver: independent pharmacies, supermarket chains, and online pharmacies (market-dependent)
Who sells PROMETH VC PLAIN and what is the competitive set?
The competitive set for promethazine-based cough syrups is dominated by:
- Other branded multi-ingredient cough-cold liquids
- Generic promethazine-based syrup and generic pheniramine/dextromethorphan variants (where composition overlaps)
- Non-promethazine substitutes (notably dextromethorphan-based cough syrups and non-sedating antihistamine options), depending on the labeled indications and age restrictions
Competitive dynamics
- Competitive price compression is typical in symptomatic OTC categories because formulations are easy to replicate and switching is common.
- Branding and distribution agreements usually matter more than IP for steady-state OTC sales once branded exclusivity expires.
What market dynamics determine pricing, demand, and volume for this drug?
Key demand and pricing forces that shape financial trajectory in OTC cough/cold products:
Pricing power and substitution
- Price is pressured by generic and private-label liquids that match active ingredient classes (where legally allowed by label and composition).
- Switching is driven by perceived effectiveness, sedation tolerability, and dosing convenience.
Regulatory and labeling constraints
- Promethazine has safety-related label constraints in multiple jurisdictions (sedation, respiratory depression risk), which can narrow eligible patient populations and can shift consumer behavior toward non-sedating or non-promethazine alternatives.
Seasonality
- Sales typically peak during colder months and flu seasons. Even without numeric inputs, the financial profile generally follows a winter-weighted demand curve.
Supply chain and manufacturing risk
- Syrup products are sensitive to raw material availability and packaging constraints (bottles, dosing cups, and cartons), which can create short-run distribution bottlenecks.
How does PROMETH VC PLAIN typically generate revenue and margins?
A typical branded OTC syrup financial model:
- Revenue depends on winter sell-through and refill cadence through retail.
- Gross margins often compress as competitors increase shelf presence and price.
- Brand spend influences retailer stocking but is bounded by advertising rules and the need to defend category share.
Financial trajectory pattern in OTC symptomatics
- Early period: brand build through distribution expansion and promotional pricing
- Mid period: steady sales with periodic share gains if the product holds a stable formulary position
- Later period: share erosion to generics or alternative branded competitors if IP protection weakens or if reformulations emerge
When does PROMETH VC PLAIN lose exclusivity, and what timing matters for generic entry?
A definitive exclusivity and patent-loss timeline requires a specific product jurisdiction, NDA/ANDA/market authorization identifiers, and the Orange Book (US) or national register entries for the exact “PROMETH VC PLAIN” SKU. Without those identifiers, the exclusivity schedule cannot be stated with required precision.
Under standard OTC small-molecule dynamics, exclusivity usually erodes through:
- expiration of composition and manufacturing patents (if any are listed)
- expiration of regulatory data exclusivity (if applicable)
- generic launches targeting the same active ingredient combination and dosage form
This timing drives the sharpest year-over-year margin pressure events in OTC markets.
What patents protect PROMETH VC PLAIN and how strong is the estate?
Patent strength for OTC combination syrups is typically evaluated via:
- composition-of-matter patents covering the combination and/or ratios
- formulation patents covering stability, solubility, or excipient systems
- manufacturing-process patents (scale, mixing, sterilization or filtration steps as relevant)
- method-of-use patents (less common for classic symptomatic cough-cold products)
A complete patent landscape depends on the exact active ingredient list and the relevant registries. Without registered identifiers and patent numbers tied to the exact marketed SKU, an accurate count and expiration map cannot be produced.
What is the Orange Book status of PROMETH VC PLAIN?
Orange Book status is determined by whether the product is an approved NDA/ANDA-referenced listed drug with active patent listings. “PROMETH VC PLAIN” is not uniquely identifiable from the name alone, and Orange Book mapping requires exact sponsor/active ingredient/NDC match.
Without those matching keys, Orange Book status and listed patent expiry cannot be stated as a factual dataset.
What generic entry risks exist for PROMETH VC PLAIN?
Generic risk for a promethazine cough/cold liquid generally concentrates in:
- composition overlap: same actives at similar strengths and intended use labeling
- formulation substitutability: comparable excipients and stability claims
- bioequivalence feasibility: syrups typically require BA/BE studies or leverage existing references, depending on jurisdiction
Typical launch risk pattern
- If exclusivity is gone and the formulation is not protected, multiple generic entrants can compress price within one to two seasons.
- If combination-specific patents exist, entrants may be forced into design-around formulations or delayed launches until patent expiry.
Which companies are challenging PROMETH VC PLAIN via Paragraph IV (if in the US)?
Paragraph IV challenges apply to ANDAs against listed patents in the US Orange Book. Identifying Paragraph IV filers requires:
- the listed drug name
- ANDA number
- patent numbers asserted
Without registrable linkage for “PROMETH VC PLAIN,” Paragraph IV challengers cannot be provided as factual names.
What patent litigation affects PROMETH VC PLAIN, and what settlement outcomes matter?
Patent litigation impacts financial trajectory by:
- delaying generic approval and launch
- requiring license payments or agreed entry dates
- creating inducement or “authorized generic” carve-outs
A litigation timeline requires docket-level data tied to the exact product and patent family. Without those identifiers, no enforceable facts on filings, outcomes, or settlement dates can be provided.
How does PROMETH VC PLAIN compare with other promethazine-based cough syrups?
The most decision-relevant comparisons in this class are:
- active ingredient combinations and strengths (ratio drives patent and generic overlap)
- sedative warning prominence and labeled age restrictions
- dosing interval and package size economics
- retailer brand preference and substitution patterns
In practice, the closest “shelf substitutes” typically win most often on:
- price-per-dose
- availability during peak winter demand
- perceived efficacy for cough vs runny nose symptoms
What are the FDA regulatory pathway and approval constraints for this drug?
For a branded syrup product, regulatory constraints include:
- labeling for contraindications and warnings
- child safety considerations (promethazine class warnings)
- manufacturing compliance (GMP, sterility/bioburden controls if relevant)
- post-marketing commitments and stability requirements
A pathway statement requires an FDA application number or foreign equivalent authorization record. No such identifiers are present here, so the exact pathway cannot be stated as a dataset.
What commercial scenario best explains PROMETH VC PLAIN’s financial trajectory?
In the absence of specific financial statements, the most robust OTC trajectory model is scenario-based around share erosion and seasonality:
Scenario 1: Stable exclusivity / limited competitors
- sales track winter demand
- gross margin holds until competitive pricing intensifies
- mid-single digit to low-double-digit annual growth is possible in a healthy category, depending on distribution
Scenario 2: Generic or reformulated competitor entry
- first winter after generic availability typically produces the biggest price compression
- branded share falls; retailer shelf space reallocates
- margin compresses through promo and trade terms
Scenario 3: Repositioning or shrinkage in target population
- if safety warnings reduce eligible usage or if consumers switch to alternatives, volume growth slows
- revenue growth becomes distribution-driven rather than brand-driven
Revenue exposure map: which variables most influence P&L for PROMETH VC PLAIN?
The P&L sensitivity stack in OTC syrups:
- Net price: affected by generic shelf competition and retailer promotions
- Mix: packet size, strength, and channel shift
- Volume: seasonality and category health
- Trade spend: retailer slotting, promotions, and co-op marketing
- Returns and spoilage: syrup shelf-life and distribution logistics
- Regulatory costs: label maintenance, inspections, and potential reformulations
Key data that would usually be compiled for an investment or licensing decision
For PROMETH VC PLAIN, a complete diligence pack normally includes:
- product-level NDC-to-active ingredients mapping
- Orange Book listed patents and expiries (US) or equivalent patent register data (non-US)
- market size by country, brand share, and channel distribution
- wholesaler inventory and sell-through by quarter
- net sales and gross margin trends over at least 8 quarters
- executed distribution and licensing agreements
- litigation dockets and settlement terms
- adverse event trends that could affect label restrictions
No product identifiers or financial statements are provided here, so a quantified financial trajectory cannot be produced as a factual forecast.
Key Takeaways
- PROMETH VC PLAIN sits in a promethazine-containing OTC symptomatic relief market where substitution and seasonal demand largely drive performance.
- The financial trajectory is typically shaped by winter sell-through, promotional intensity, and how quickly price competition emerges once exclusivity weakens.
- A precise exclusivity, Orange Book, patent-portfolio strength, and generic/Paragraph IV risk assessment requires product-level identifiers and registry mappings that are not provided in the prompt.
FAQs
1) Is PROMETH VC PLAIN an NDA, ANDA, or OTC monograph product?
A definitive classification depends on the exact jurisdiction and application record tied to the marketed SKU.
2) What are the most likely “design-around” strategies for generics of promethazine cough syrups?
Typically changes in active ingredient combination, strengths, excipient system, and labeling-dependent positioning.
3) How does seasonality typically change quarterly revenue for OTC cough-cold syrups?
Revenue usually concentrates in cold/flu seasons with weaker summer performance.
4) What label safety constraints most affect promethazine cough products?
Sedation and respiratory risk warnings that can shift eligible patient usage and consumer preference toward alternatives.
5) What is the usual economic impact of generic entry on branded OTC syrup margins?
Price compression and higher trade/promotional spending usually reduce net price and gross margin in the winter following entry.
References
No sources cited.
